These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 27530514)

  • 1. Cardioprotective role of peroxisome proliferator-activated receptor-γ agonist, rosiglitazone in a unique murine model of diabetic cardiopathy.
    Giri SR; Bhoi B; Jain MR; Gatne MM
    Life Sci; 2016 Oct; 162():1-13. PubMed ID: 27530514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
    Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
    J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation.
    Wang X; Liu X; Zhan Y; Lavallie ER; Diblasio-Smith L; Collins-Racie L; Mounts WM; Rutkowski JL; Xu X; Goltsman I; Abassi Z; Winaver J; Feuerstein GZ
    J Pharmacol Exp Ther; 2010 Sep; 334(3):820-9. PubMed ID: 20519551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
    Ihm SH; Chang K; Kim HY; Baek SH; Youn HJ; Seung KB; Kim JH
    Basic Res Cardiol; 2010 May; 105(3):399-407. PubMed ID: 19902320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
    Rose M; Balakumar P; Singh M
    Pharmacology; 2007; 80(2-3):177-84. PubMed ID: 17570955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats.
    Pelzer T; Jazbutyte V; Arias-Loza PA; Segerer S; Lichtenwald M; Law MP; Schäfers M; Ertl G; Neyses L
    Biochem Biophys Res Commun; 2005 Apr; 329(2):726-32. PubMed ID: 15737646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
    Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone, a peroxisome proliferator-activated receptor γ stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity.
    El-Bassossy HM; Abo-Warda SM; Fahmy A
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):643-9. PubMed ID: 22594672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
    Allen T; Zhang F; Moodie SA; Clemens LE; Smith A; Gregoire F; Bell A; Muscat GE; Gustafson TA
    Diabetes; 2006 Sep; 55(9):2523-33. PubMed ID: 16936200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
    Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
    Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
    Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L
    Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
    Desouza CV; Murthy SN; Diez J; Dunne B; Matta AS; Fonseca VA; McNamara DB
    J Cardiovasc Pharmacol Ther; 2003 Dec; 8(4):297-305. PubMed ID: 14740079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?
    Goltsman I; Khoury EE; Winaver J; Abassi Z
    Pharmacol Ther; 2016 Dec; 168():75-97. PubMed ID: 27598860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (+)-Z-Bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats.
    Banz WJ; Davis J; Steinle JJ; Adler S; Oitker J; Winters TA; Higginbotham DA; Hou Y; Henry N; Peterson R; Meyers CY
    Obes Res; 2005 Nov; 13(11):1915-24. PubMed ID: 16339123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rosiglitazone (PPAR γ agonist) on the myocardium in non-hypertensive diabetic rats (PPAR γ).
    Abou Daya K; Abu Daya H; Nasser Eddine M; Nahhas G; Nuwayri-Salti N
    J Diabetes; 2015 Jan; 7(1):85-94. PubMed ID: 24548695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
    Gaikwad AB; Viswanad B; Ramarao P
    Pharmacol Res; 2007 May; 55(5):400-7. PubMed ID: 17369046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.